Table 4.
Relationships of AIP and all-cause and CVD-specific mortality in age, gender, race, BMI, CVD, DM, antihyperlipidemic agents use and hypotensive drugs use subgroups
| Subgroups | AIP levels | All-cause mortality | CVD-specific mortality | ||
|---|---|---|---|---|---|
| HR (95% CI) | P | HR (95% CI) | P | ||
| Age < 40 | 3.25–4.34 | Ref | Ref | ||
| < 3.25 | 1.55 (0.88–2.73) | 0.129 | 0.98 (0.44–2.20) | 0.967 | |
| > 4.34 | 1.37 (0.85–2.21) | 0.190 | 0.70 (0.33–1.49) | 0.355 | |
| 40 ≤ Age < 60 | 3.25–4.34 | Ref | Ref | ||
| < 3.25 | 1.30 (0.98–1.72) | 0.068 | 1.19 (0.74–1.90) | 0.472 | |
| > 4.34 | 1.45 (1.11–1.88) | 0.006 | 1.21 (0.80–1.81) | 0.363 | |
| Age ≥ 60 | 3.25–4.34 | Ref | Ref | ||
| < 3.25 | 1.10 (0.98–1.23) | 0.121 | 1.28 (1.05–1.57) | 0.016 | |
| > 4.34 | 1.05 (0.91–1.21) | 0.486 | 1.36 (1.11–1.68) | 0.004 | |
| Male | 3.25–4.34 | Ref | Ref | ||
| < 3.25 | 1.27 (1.10–1.48) | 0.001 | 1.37 (1.06–1.77) | 0.015 | |
| > 4.34 | 1.12 (0.94–1.32) | 0.196 | 1.17 (0.90–1.53) | 0.232 | |
| Female | 3.25–4.34 | Ref | Ref | ||
| < 3.25 | 1.16 (1.00-1.34) | 0.044 | 1.23 (0.95–1.59) | 0.112 | |
| > 4.34 | 1.20 (1.00-1.44) | 0.046 | 1.29 (1.03–1.63) | 0.028 | |
| BMI ≤ 25 | 3.25–4.34 | Ref | Ref | ||
| < 3.25 | 1.05 (0.87–1.27) | 0.627 | 1.03 (0.72–1.47) | 0.88 | |
| > 4.34 | 0.99 (0.76–1.30) | 0.962 | 1.11 (0.73–1.68) | 0.633 | |
| BMI > 25 | 3.25–4.34 | Ref | Ref | ||
| < 3.25 | 1.26 (1.09–1.45) | 0.001 | 1.40 (1.10–1.78) | 0.007 | |
| > 4.34 | 1.22 (1.04–1.43) | 0.013 | 1.31 (1.05–1.63) | 0.017 | |
| Mexican American | 3.25–4.34 | Ref | Ref | ||
| < 3.25 | 1.39 (0.94–2.05) | 0.097 | 1.16 (0.66–2.03) | 0.611 | |
| > 4.34 | 1.18 (0.84–1.66) | 0.345 | 1.20 (0.69–2.06) | 0.516 | |
| Other Hispanic | 3.25–4.34 | Ref | Ref | ||
| < 3.25 | 1.02 (0.66–1.56) | 0.930 | 1.01 (0.42–2.45) | 0.977 | |
| > 4.34 | 0.67 (0.42–1.08) | 0.100 | 0.63 (0.30–1.31) | 0.214 | |
| Non-Hispanic White | 3.25–4.34 | Ref | Ref | ||
| < 3.25 | 1.22 (1.06–1.41) | 0.005 | 1.34 (1.06–1.69) | 0.013 | |
| > 4.34 | 1.18 (1.00-1.39) | 0.048 | 1.28 (1.03–1.60) | 0.024 | |
| Non-Hispanic Black | 3.25–4.34 | Ref | Ref | ||
| < 3.25 | 1.11 (0.92–1.33) | 0.284 | 1.25 (0.91–1.71) | 0.174 | |
| > 4.34 | 1.38 (1.08–1.77) | 0.010 | 1.36 (0.93-2.00) | 0.110 | |
| Other race-including multi-racial | 3.25–4.34 | Ref | Ref | ||
| < 3.25 | 0.72 (0.38–1.36) | 0.312 | 0.75 (0.25–2.25) | 0.608 | |
| > 4.34 | 1.01 (0.61–1.67) | 0.958 | 1.36 (0.53–3.45) | 0.521 | |
| Non-CVD | 3.25–4.34 | Ref | Ref | ||
| < 3.25 | 1.29 (1.14–1.46) | < 0.001 | 1.33 (1.04–1.70) | 0.026 | |
| > 4.34 | 1.25 (1.07–1.46) | 0.005 | 1.29 (1.03–1.61) | 0.026 | |
| CVD | 3.25–4.34 | Ref | Ref | ||
| < 3.25 | 0.99 (0.81–1.20) | 0.923 | 1.15 (0.92–1.43) | 0.226 | |
| > 4.34 | 0.94 (0.79–1.13) | 0.512 | 1.10 (0.80–1.50) | 0.573 | |
| Non-DM | 3.25–4.34 | Ref | Ref | ||
| < 3.25 | 1.26 (1.11–1.44) | < 0.001 | 1.26 (1.02–1.57) | 0.033 | |
| > 4.34 | 1.19 (1.05–1.35) | 0.005 | 1.27 (1.05–1.55) | 0.015 | |
| DM | 3.25–4.34 | Ref | Ref | ||
| < 3.25 | 1.01 (0.83–1.22) | 0.937 | 1.24 (0.92–1.67) | 0.163 | |
| > 4.34 | 1.09 (0.82–1.46) | 0.534 | 1.20 (0.84–1.72) | 0.319 | |
| Non-antihyperlipidemic agents | 3.25–4.34 | Ref | Ref | ||
| < 3.25 | 1.38 (1.19–1.60) | < 0.001 | 1.37 (1.04–1.81) | 0.026 | |
| > 4.34 | 1.20 (1.00-1.45) | 0.049 | 1.38 (1.12–1.70) | 0.003 | |
| Antihyperlipidemic agents use | 3.25–4.34 | Ref | Ref | ||
| < 3.25 | 1.01 (0.87–1.19) | 0.864 | 1.13 (0.89–1.45) | 0.305 | |
| > 4.34 | 1.18 (0.97–1.44) | 0.095 | 1.14 (0.83–1.56) | 0.430 | |
| Non-hypertension drug | 3.25–4.34 | Ref | Ref | ||
| < 3.25 | 1.22 (0.92–1.61) | 0.159 | 1.05 (0.64–1.71) | 0.854 | |
| > 4.34 | 1.10 (0.85–1.42) | 0.465 | 0.88 (0.56–1.39) | 0.586 | |
| Hypertension drug use | 3.25–4.34 | Ref | Ref | ||
| < 3.25 | 1.18 (1.05–1.32) | 0.007 | 1.34 (1.11–1.61) | 0.002 | |
| > 4.34 | 1.21 (1.04–1.40) | 0.012 | 1.41 (1.17–1.70) | < 0.001 | |
AIP: atherogenic index of plasma, CVD: cardiovascular disease, BMI: body mass index, DM: diabetes mellitus, HR: hazard ratio, CI: confidence interval, Ref: reference
Age subgroup: adjusted for race, education level, marital status, PIR, smoking, BMI, physical activity, antihyperlipidemic agents, DM, CVD, hypotensive drugs, eGFR, and energy intake;
Gender subgroup: adjusted for age, race, education level, marital status, PIR, smoking, BMI, physical activity, antihyperlipidemic agents, DM, CVD, hypotensive drugs, eGFR, and energy intake;
BMI subgroups: adjusted for age, race, education level, marital status, PIR, smoking, physical activity, antihyperlipidemic agents, DM, CVD, hypotensive drugs, eGFR, and energy intake;
Race subgroup: adjusted for age, education level, marital status, PIR, smoking, BMI, physical activity, antihyperlipidemic agents, DM, CVD, hypotensive drugs, eGFR, and energy intake;
CVD subgroup: adjusted for age, race, education level, marital status, PIR, smoking, BMI, physical activity, antihyperlipidemic agents, DM, hypotensive drugs, eGFR, and energy intake;
DM subgroup: adjusted for age, race, education level, marital status, PIR, smoking, BMI, physical activity, antihyperlipidemic agents, CVD, hypotensive drugs, eGFR, and energy intake;
Antihyperlipidemic agents use subgroup: adjusted for age, race, education level, marital status, PIR, smoking, BMI, physical activity, DM, CVD, hypotensive drugs, eGFR, and energy intake;
Hypertension drug use subgroup: adjusted for age, race, education level, marital status, PIR, smoking, BMI, physical activity, antihyperlipidemic agents, DM, CVD, eGFR, and energy intake